High‐throughput systems allow screening and analysis of large number of samples simultaneously under same conditions. Over recent years, high‐throughput systems have found applications in fields other than drug discovery like bioprocess industries, pollutant detection, material microarrays, etc. With the introduction of materials in such HT platforms, the screening system has been enabled for solid phases apart from conventional solution phase. The use of biomaterials has further facilitated cell‐based assays in such platforms. Here, the authors have focused on the recent developments in biomaterial‐based platforms including the fabricationusing contact and non‐contact methods and utilization of such platforms for discovery of novel biomaterials exploiting interaction of biological entities with surface and bulk properties. Finally, the authors have elaborated on the application of the biomaterial‐based high‐throughput platforms in tissue engineering and regenerative medicine, cancer and stem cell studies. The studies show encouraging applications of biomaterial microarrays. However, success in clinical applicability still seems to be a far off task majorly due to absence of robust characterization and analysis techniques. Extensive focus is required for developing personalized medicine, analytical tools and storage/shelf‐life of cell laden microarrays.

中文翻译：

---

基于生物材料的高通量平台的最新进展

高通量系统允许在相同条件下同时筛选和分析大量样品。近年来，高通量系统已在除药物发现之外的其他领域中找到了应用，例如生物加工行业，污染物检测，材料微阵列等。随着此类HT平台中材料的引入，除固相以外，筛查系统也已启用常规解决方案阶段。在这种平台上，生物材料的使用进一步促进了基于细胞的测定。在这里，作者集中于基于生物材料的平台的最新发展，包括使用接触和非接触方法进行制造，以及利用此类平台来发现利用生物实体具有表面和体积特性的相互作用的新型生物材料。最后，作者已经详细阐述了基于生物材料的高通量平台在组织工程和再生医学，癌症和干细胞研究中的应用。研究表明，生物材料微阵列的应用令人鼓舞。然而，主要由于缺乏可靠的表征和分析技术，临床应用的成功似乎仍然是遥不可及的任务。开发个性化药物，分析工具以及载有细胞的微阵列的储存/保存期限需要广泛关注。主要由于缺乏可靠的表征和分析技术，临床应用的成功似乎仍然遥不可及。开发个性化药物，分析工具以及载有细胞的微阵列的储存/保存期限需要广泛关注。主要由于缺乏可靠的表征和分析技术，临床应用的成功似乎仍然遥不可及。开发个性化药物，分析工具以及载有细胞的微阵列的储存/保存期限需要广泛关注。